<DOC>
	<DOCNO>NCT01760525</DOCNO>
	<brief_summary>This first human phase I study single agent CGM097 patient advance solid tumor progress despite standard therapy standard therapy exist . The tumor must characterize p53wt status . The study consist dose escalation part patient receive escalate dos CGM097 , dose expansion part patient give CGM097 maximum tolerate dose ( MTD ) Recommended Phase 2 Dose ( RP2D ) . Each dose escalation step decide base recommendation adaptive Bayesian logistic regression model ( BLRM ) .</brief_summary>
	<brief_title>A Phase I Dose Escalation Study CGM097 Adult Patients With Selected Advanced Solid Tumors</brief_title>
	<detailed_description>This multi-center , open-label , dose finding , phase I study single agent CGM097 , administer patient advance solid tumor progress despite standard therapy standard therapy exists . Patients ' tumor must characterize p53wt status . The study consist dose escalation part , cohort three six newly enrol patient receive escalate dos CGM097 , dose expansion part , patient give CGM097 maximum tolerate dose ( MTD ) Recommended Phase 2 Dose ( RP2D ) . Novartis site investigator jointly decide dose escalation step base recommendation adaptive Bayesian logistic regression model ( BLRM ) . If safety data indicate low increment suggest BLRM , next dose level ( DL ) adjust accordingly .</detailed_description>
	<criteria>Patient advance solid malignancy progress despite standard therapy , effective standard therapy exist Tumor patient p53wt Evaluable disease determine RECIST 1.1 WHO performance status 02 Exclusion criterion : Prior treatment CGM097 p53/HDM2interaction inhibitor Patient symptomatic grow CNS metastatic lesion Concurrent malignancy Clinically significant cardiac disease define protocol Diagnosis acute chronic pancreatitis Concomitant therapy precludes enrollment , define protocol Women childbearing potential , unless use highly effective method contraception dose 2 week study drug discontinuation Pregnant nursing woman Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>p53 , solid tumor</keyword>
</DOC>